Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01135316 · ClinicalTrials.gov registry record

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

A clinical trial, sponsored by Lantheus Medical Imaging.

Completed
Registry status
2
Enrollment target

NCT01135316: Completed study, sponsored by Lantheus Medical Imaging.

NCT01135316 is a clinical trial that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01135316 has completed, sponsored by Lantheus Medical Imaging.

COMPLETED
Registry status
2 participants
Enrollment target

Study Summary

Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.

Interventions

  • DRUG Ablavar

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2009-10
Est. Completion 2013-09
Lantheus Medical Imaging

22 total trials

What the finished NCT01135316 record still lists

NCT01135316 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Ablavar is the first listed.

NCT01135316 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01135316 about?

NCT01135316 is a clinical study titled "Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR". Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.

What is the current status of trial NCT01135316?

This trial is currently completed. The enrollment target is 2 participants. The study started on 2009-10. Estimated completion is 2013-09.

What interventions are being tested in trial NCT01135316?

The interventions under investigation include: Ablavar (DRUG).

Who is sponsoring clinical trial NCT01135316?

This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01135316, the US trial registry maintained by the National Library of Medicine. NCT01135316 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.